Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Phosphate Binders on Vadadustat PK
NCT04299633Phase 1Completed
- Sponsor
- Akebia Therapeutics
- Start
- Jun 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of vadadustat in anemia of chronic kidney disease (CKD-A) (3 arms), sponsored by Akebia Therapeutics. Primary endpoints: Vadadustat area under the plasma concentration-time curve from time 0 to the last quantifiable concentration, Vadadustat area under the plasma concentration-time curve from time 0 to infinity and 1 more. Started Jun 2020; status: completed.
02
Drugs
vadadustat
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT04299633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04299633.